Control of drooling using transdermal scopolamine skin patches. A case report.
Transdermal scopolamine has been shown to be very useful in the management of drooling, particularly in patients with neurological or neuropsychiatric disturbances or severe developmental disorders. In this paper, we present the case of a 24-year-old patient with a diagnosis of cerebral palsy and a severe problem of drooling, exacerbated by marked mandibular prognathism. After exclusion of other therapeutic alternatives, it was decided to use sustained-release transdermal scopolamine patches (Scopoderm TTS). This technique consists of the application every three days of a patch with 1.5 mg of scopolamine in the area of the mastoid apophysis; the patch releases a dose of 0.5 mg of the active substance over each 24 hour period. The patient underwent periodic clinical and laboratory follow-up over a period of three years, achieving satisfactory results with no significant undesirable effects.
Mato Montero
Abigail
A
Departamento de Estomatología, Unidad de Pacientes Especiales, Facultad de Medicina y Odontología, Universidad de Santiago de Compostela, Spain.
Limeres Posse
Jacobo
J
Tomás Carmona
Inmaculada
I
Fernández Feijoo
Javier
J
Diz Dios
Pedro
P
D000279:Administration, Cutaneous; D000328:Adult; D002547:Cerebral Palsy / Q000150:complications*; D006801:Humans; D008607:Intellectual Disability / Q000150:complications; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D011378:Prognathism / Q000150:complications; D012601:Scopolamine / Q000008:administration & dosage*; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology
D018727:Muscarinic Antagonists; D012601:Scopolamine